Τίτλος:
Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: Recent advances in the field of immunotherapy have significantly prolonged the survival of patients with aggressive carcinomas, but the role of immunotherapy in neuroendocrine neoplasms (NENs) remains to be elucidated. Methods and results: We report a patient diagnosed with a well-differentiated grade 3 pancreatic NEN (pNEN) and type 3 liver metastases who received compassionate nivolumab as a fifth line treatment and achieved a durable partial response of more than 34 months. We have performed a systematic review to the literature on tumor microenvironment and potential biomarkers in the field of NEN including the tumor mutational burden, the tumor infiltrating lymphocytes, the programmed cell death ligand 1, and the mismatch repair system. The potential role of the immune system modulation together with a critical assessment of the recent phase II clinical studies in NEN including monotherapy with anti-PD-1/PD-L1 monoclonal antibodies, and combination therapies including anti-PD-1 along with anti-CTLA-4 monoclonal antibodies are also provided. Conclusion: Immunotherapeutics are gaining a post in the field of NENs in cases progressing during the course of the disease, dictating urgently the identification of biomarkers that will enable selection of NEN patients who may benefit from this treatment. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Συγγραφείς:
Koumarianou, A.
Kaltsas, G.A.
Chatzellis, E.
Kyriakopoulos, G.
Kolomodi, D.
Alexandraki, K.I.
Περιοδικό:
Endocrine Development
Λέξεις-κλειδιά:
biological marker; capecitabine; cisplatin; cytotoxic T lymphocyte antigen 4; etoposide; everolimus; fluorodeoxyglucose f 18; fluorouracil; folinic acid; Ki 67 antigen; monoclonal antibody; nivolumab; octreotide; pembrolizumab; programmed death 1 ligand 1; programmed death 1 receptor; temozolomide; monoclonal antibody; nivolumab; programmed death 1 ligand 1, acute kidney failure; apoptosis; Article; cancer immunotherapy; cell death; chemoradiotherapy; fluorescence in situ hybridization; follow up; histology; human; human tissue; immune system; immunohistochemistry; liver biopsy; liver metastasis; male; metastasis; microsatellite instability; mismatch repair; monotherapy; neuroendocrine carcinoma; neuroendocrine tumor; nuclear magnetic resonance imaging; overall survival; pancreas islet cell tumor; positron emission tomography; positron emission tomography-computed tomography; regulated cell death; thyroidectomy; treatment response; tumor associated leukocyte; tumor microenvironment; case report; immunotherapy; neoplasm, Antibodies, Monoclonal; B7-H1 Antigen; Humans; Immunotherapy; Neoplasms; Neuroendocrine Tumors; Nivolumab; Tumor Microenvironment
DOI:
10.1007/s12020-021-02639-8
